Latest News

A qualitative, interview-based analysis identified 7 distinct roles played by hematologists relating to shared decision making for patients with advanced lymphoma or leukemia.
Multidisciplinary Teams Are Needed for Multidimensional Support in Blood Cancers

February 23rd 2023

A qualitative, interview-based analysis identified 7 distinct roles played by hematologists relating to shared decision making for patients with advanced lymphoma or leukemia.

Patients with chronic lymphocytic leukemia and small lymphocytic leukemia can now receive treatment with zanubrutinib following its approval by the FDA.
FDA OKs Zanubrutinib to Treat Leukemia Subtypes

January 19th 2023

Moxetumomab pasudotox-tdfk, approved as a treatment for relapsed/refractory hairy cell leukemia in 2018, will be withdrawn from the United States market in July 2023.
Hairy Cell Leukemia Drug Moxetumomab Pasudotox-tdfk to be Withdrawn in the United States Market

January 17th 2023

Revumenib, which was given a breakthrough therapy designation by the FDA, may be beneficial in the management of relapsed or refractory KMT2A-rearranged acute leukemia based on data from the phase 1 AUGMENT-101 trial.
FDA Grants Breakthrough Therapy Designation to Revumenib for Relapsed/Refractory KMT2Ar Acute Leukemia

December 6th 2022

Recap: Finding the Optimal Dose of Ponatinib for Chronic Phase CML
Recap: Finding the Optimal Dose of Ponatinib for Chronic Phase CML

May 27th 2022

More News